A Phase II Neoadjuvant Study of Palbociclib in Combination with Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this research study is to look at how your tumor responds to treatment with a combination of three drugs: letrozole, trastuzumab, and palbociclib. We will also be looking at the side effects that are associated with this combination of drugs.
Description
This study will look at how subject's tumor responds to treatment with a combination of three drugs: letrozole, trastuzumab, and palbociclib. Researchers will also be looking at the side effects that are associated with this combination of drugs.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
breast cancer
-
Age: Between 18 Years - 100 Years
-
Gender: Female
Updated on
20 Nov 2022.
Study ID: 1710739233 (201610019)